Douglas W. Calder's most recent trade in Zevra Therapeutics Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Douglas W. Calder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Renovaro Biosciences Inc | Douglas W. Calder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 120,968 | 120,968 | - | - | Option to purchase shares of common stock | |
| Zevra Therapeutics Inc | Douglas W. Calder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 39,200 | 39,200 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Douglas W. Calder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 58,800 | 58,800 | - | - | Stock Option (right to buy) |